样式: 排序: IF: - GO 导出 标记为已读
-
Clot waveform analysis in acute promyelocytic leukemia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-11-09 Malek Terras,Wijden El Borgi,Wafa Betbout,Rabeb Jaied,Fatma Ben Lakhal,Sarra Fekih Salem,Ons Ghali,Emna Gouider
The aim of this study was to evaluate the activated partial thromboplastin time (APTT) and prothrombin time (PT)-based clot waveform analysis (CWA) in patients diagnosed with acute promyelocytic leukemia (APL). APTT-based and PT-based CWA parameters of patients diagnosed with APL were analyzed and compared with healthy volunteers. Four APTT-CWA parameters were noted, maximum velocity corresponding
-
Interpreting coagulation mixing study results in the era of direct oral anticoagulants. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-11-07 Moon Joo Kim,Eric Salazar,Bonnie Philips,Lawrence Rice,Brian Castillo,Christopher Leveque,Jian Chen
Interpretation of coagulation mixing studies is complicated by interference arising from direct oral anticoagulants (DOACs), which are increasingly prescribed. In this retrospective study, we reviewed 1035 consecutive coagulation mixing studies performed from 2017 to 2021. Three hundred and ninety-nine cases with normal prothrombin time (PT) and activated partial thromboplastin time (aPTT) were excluded
-
True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-11-03 Alessandro Laganà,Silvia Maria Trisolini,Raffaele Maglione,Shafii Bafti Mahnaz,Stefano Imperatore,Diana Vitullo,Saveria Capria
Acquired thrombotic thrombocytopenic purpura (aTTP) is a medical emergency requiring urgent plasma exchange and immunosuppressive agents. Recently, the therapeutic options have been expanded by the approval of a novel anti-von Willebrand factor (vWF) nanobody, caplacizumab, inhibiting vWF-platelet aggregation. Here, we present a rare case of a patient affected by immune-mediated TTP (iTTP) reporting
-
Utility of the international society on thrombosis and hemostasis-bleeding assessment tool in the diagnosis of patients who suspected of platelet function disorders. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-11-03 Massoumeh Shahbazi,Minoo Ahmadinejad,Amir Teimourpour
The ISTH-BAT is a structured bleeding assessment tool to record and help diagnose patients with possible bleeding disorders. However, a few studies evaluated the utility of ISTH-BAT in diagnosing patients with platelet function defects (PFDs). In this study, we evaluated the diagnostic utility of ISTH-BAT in predicting PFDs among patients suspected of PFDs. Forty patients suspected of PFDs and 21 normal
-
Epidemiological study of hereditary hemorrhagic disorders in Najaf province, Iraq. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-30 Ezzate Hasson Ajeena,Ali Adil Saleem
Hemophilia and Von Willbrand disease (VWD) are the most well known types of hereditary hemorrhagic disorders (HHD). Hemophilia affects about 200 000 people worldwide, while VWD affects about 80 000. Because there is a scarcity of epidemiologic studies on hemophilia in Iraq, this study was carried out to evaluate the prevalence and incidence trends, as well as to identify some clinical and epidemiological
-
Combination of aspirin and rosuvastatin for reduction of venous thromboembolism in severely injured patients: a double-blind, placebo-controlled, pragmatic randomized phase II clinical trial (The STAT Trial). Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-27 Christopher D Barrett,Hunter B Moore,Ernest E Moore,James Chandler,Angela Sauaia
INTRODUCTION Venous thromboembolism (VTE) remains a significant source of postinjury morbidity and mortality. Beta-hydroxy beta-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (rosuvastatin) significantly reduced pathologic clotting events in healthy populations in a prior trial. Furthermore, acetylsalicylic acid (ASA) has been shown to be noninferior to prophylactic heparinoids for VTE prevention
-
Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-20 Agustina Saladino,María L Gonzalez,Fernando A Chuliber,Marcelo M Serra
Glanzmann's Thrombasthenia (GT) is a rare hemorrhagic condition caused by a platelet surface receptor disorder of the glycoprotein (GP) IIb/IIIa. Symptoms of GT are various forms of hemorrhages, such as purpura, epistaxis and menorrhagia. Gastrointestinal bleeding (GIB) is a rare expression of the condition and may occur due to traumas in the GI tract or as a consequence of gastrointestinal angiodysplasia
-
New score for predicting thromboembolic events in patients with atrial fibrillation using direct oral anticoagulants. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-19 Fuxin Ma,Jiana Chen,Sijie Chang,Nianxu Huang,Wang Zhang,Hengfen Dai,Qiaowei Zheng,Ruijuan Li,Xiangsheng Lin,Yuxin Liu,Xiaoming Du,Jun Su,Xiaohong Huang,Xia Chen,Wei Hu,Xiumei Liu,Yanxia Zhang,Ping Gu,Jinhua Zhang
Determinants of thrombotic events remain uncertain in patients with atrial fibrillation treated with direct oral anticoagulants (DOACs). Our aim was to identify risk factors associated with thromboembolism in patients with at atrial fibrillation on DOACs and to construct and externally validate a predictive model that would provide a validated tool for clinical assessment of thromboembolism. In the
-
Efficacy of adjusted weight-based dosing of desmopressin (1-deamino-8-d-arginine vasopressin in type 1 von Willebrand disease. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-13 Craig D Seaman
-
Assessment of coagulation assays on Roche Cobas t711 analyzer: performance and clinical implications. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-11 María Ordóñez-Robles,Oscar D Pons-Belda,María José Moína,Ángel Bernardo-Gutiérrez,Belén Prieto-García
OBJECTIVES We performed an analytical assessment of five coagulation tests [i.e. prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, thrombin time (TT) and D-dimer] on the Roche Cobas t711 analyzer and a comparison study with the methodology in use at our laboratory (i.e. Werfen ACL Top 750 analyzer), expanding the analysis to the clinical implications of Cobas t711 implementation
-
Fibrinogen Aα gene genotyping in patients with inherited afibrinogenemia deficiency; a novel mutation in Iranian afibrinogenemia patients. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-10 Ali Moazzeni,Majid Naderi,Akbar Dorgalaleh,Shaban Alizadeh
BACKGROUND Congenital fibrinogen deficiencies (CFD) are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene. Here in, the sequences of Aα chain of fibrinogen (FGA) in patients with inherited afibrinogenemia disorder in south-eastern of Iran were analysed. METHODS The FGA gene exons were amplified using PCR
-
Diagnosis and treatment of coagulopathy using thromboelastography with platelet mapping is associated with decreased risk of pulmonary failure in COVID-19 patients. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-10-03 Tjasa Hranjec,Mackenzie Mayhew,Bradley Rogers,Rachele Solomon,Deborah Hurst,Michael Estreicher,Alberto Augusten,Aaron Nunez,Melissa Green,Shivali Malhotra,Randy Katz,Andrew Rosenthal,Sara Hennessy,Paul Pepe,Robert Sawyer,Juan Arenas
INTRODUCTION Treatment of coronavirus disease 2019 (COVID-19) patients may require antithrombotic and/or anti-inflammatory medications. We hypothesized that individualized anticoagulant (AC) management, based on diagnosis of coagulopathy using thromboelastography with platelet mapping (TEG-PM), would decrease the frequency of pulmonary failure (PF) requiring mechanical ventilation (MV), mitigate thrombotic
-
Coagulation parameters in very preterm infants. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-28 Beril Yasa,Elif Kirit,Asuman Coban,Leyla Bilgin,Gizem Kavram,Zeynep Ince
The aim of this study was to define normal percentile values of coagulation parameters in preterm infants below 32 weeks of gestational age. This retrospective cohort study was conducted at Istanbul Medical Faculty. Preterm infants who were born prior to 32 weeks of gestation, between 2011 and 2021 were included and evaluated for coagulation parameters. Blood samples obtained through umbilical catheters
-
The impact of vascular endothelial glycocalyx on the pathogenesis and treatment of disseminated intravascular coagulation. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-28 Jingjing Cao,Yi Chen
Disseminated intravascular coagulation (DIC) is a complex disorder characterized by widespread activation of blood clotting mechanisms throughout the body. Understanding the role of vascular endothelial glycocalyx in the pathogenesis and treatment of DIC is crucial for advancing our knowledge in this field. The vascular endothelial glycocalyx is a gel-like layer that coats the inner surface of blood
-
Evaluation of acquired and hereditary risk factors for the development of thromboembolism in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-26 Vildan Gürsoy,Sevil Sadri,Selime Ermurat
Although the contribution of antiphospholipid antibodies (aPL) to thrombolembolism in systemic lupus erythematosus (SLE) is well known, there is not enough data on the contribution of various hereditary thrombophilic factors. In this study, we aimed to determine acquired and hereditary thrombophilic factors in adult patients with SLE. A total of 93 SLE patients (87 women and 6 men) were included. Data
-
Is dynamic change in mean platelet volume related with composite endpoint development after transcatheter aortic valve replacement? Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-20 Orhan Ince,Kamil Gulsen,Sevgi Ozcan,Esra Donmez,Murat Ziyrek,Irfan Sahin,Ertugrul Okuyan
Aortic valve stenosis (AS) is the most common valvular disease, and surgical or transcatheter aortic valve replacement (TAVR) are the treatment options. Diminish in platelet production or dysfunction may occur due to shear stress, advanced age, and other coexisting diseases in AS patients. Bleeding is one of the complications of TAVR and associated with increased mortality. MPV (mean platelet volume)
-
Quantifying time from last dose: do direct oral anticoagulant assays correlate with patient's reported last dose. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-18 Brandon Stretton,Joshua Kovoor,Stephen Bacchi,Aashray Gupta,Suzanne Edwards,Jir Ping Boey,Samuel Gluck,Benjamin Reddi,Guy Maddern,Mark Boyd
INTRODUCTION In the absence of a patient's last direct oral anticoagulant (DOAC) dose time, best practice regarding preoperative DOAC cessation remains unclear. The aim of this study was to investigate, in a real-life patient cohort, if there was an association between subjective patient recall and objective DOAC assay titre. METHODS/MATERIALS A multicentre cohort study of consecutive surgical inpatients
-
Protein C and protein S deficiencies are associated with increased risk of deep vein thrombosis in pregnant women using oral contraceptives. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-12 Elyasa M Elfaki,Abdulrahman Algarni,Tagwa Yousif Elsayed Yousif,Alneil Hamza,Ezeldine K Abdalhabib,Husham O Elzein,Eldaw M Habiballah,Osama A B Ahmed,Hussam Ali Osman,Praveen Kumar,Asaad M A Babker,Ayman H Alfeel,Muhammad Saboor
BACKGROUND Oral contraceptives are commonly taken by women and are known to increase the risk of venous thromboembolism (VTE). OBJECTIVE The aim of this study was to investigate the association between oral contraceptive use and natural anticoagulants, that is, protein C (PC), protein S (PS), and antithrombin in pregnant women with deep vein thrombosis (DVT). MATERIALS AND METHODS This case-control
-
Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-08 William J Archibald,Peter A Kouides,Majed A Refaai,Neil A Lachant
Acquired bleeding disorders because of an autoimmune phenomenon are rare events. Acquired von Willebrand disease (aVWD) has been estimated as having a prevalence of 400 per million in the general population. Acquired hemophilia A (AHA), the most common of the acquired hemophilias, has an estimated incidence of 1.3-1.5 cases per million per year. Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1
-
Safety of Sinopharm vaccine in patients with congenital bleeding disorders under on-demand therapy: a preliminary report. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-01 Amin Shahsavani,Sezaneh Haghpanah,Tahereh Zarei,Asghar Bazrafshan,Mehran Karimi
-
Disseminated intravascular coagulation in acute leukemia patients. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-09-01 Tomoyuki Kawada
-
A study of fibrinolytic system components in donor groups depending on various titers of circulating anti-SARS-CoV-2 IgG in the bloodstream. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-08-09 Antonina Rachkovska,Daryna Krenytska,Vitalii Karbovskyy,Nataliia Raksha,Tetiana Halenova,Tetiana Vovk,Olexii Savchuk,Liudmyla Ostapchenko
The fibrinolytic system plays an important role in controlling blood coagulation at each stage, from thrombin generation to fibrin clot cleavage. Currently, long-term multiorgan dysfunction post-coronavirus disease 2019 (COVID-19) may include coagulation disorders. Little information is available about the potential causes of post-COVID-19 coagulopathy, but one of them may be subpopulation IgG produced
-
Reduced ADAMTS13 activity and high D-dimer levels are associated with thrombosis in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-08-02 Tipparat Penglong,Anuchit Boontanvansom,Pongtep Viboonjuntra,Boonjing Siripaitoon
INTRODUCTION Patients with systemic lupus erythematosus (SLE) have an increased risk of vascular thrombosis compared to the general population. Therefore, biomarkers for predicting the risk of thrombosis in patients with SLE are needed. METHODS In the present study, a total of 66 patients with SLE (22 with and 44 without a history of thrombosis) were enrolled. The cases with thrombosis and the controls
-
Diagnosis of Immunoglobulin G4-related disease in a child with ligneous conjunctivitis: a novel mutation in plasminogen gene and plasminogen activator inhibitor-1 polymorphism. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-27 Melike Emiroğlu,Banu Bozkurt,Halil Haldun Emiroğlu,Mustafa Koplay,Nadir Koçak,Pinar Karabağli
OBJECTIVES Ligneous conjunctivitis (LC) is a chronic conjunctivitis characterized by recurrent, firm, fibrin-rich, woody pseudomembranes on the palpebral conjunctiva. It is an ultrarare autosomal recessive disease associated with congenital plasminogen (PLG) deficiency due to mutations in the PLG gene (6q26). Immunoglobulin G4-related disease (IgG4-RD) is an idiopathic, systemic fibroinflammatory disease
-
The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-19 Yusuke Okayama,Masato Bingo,Kazuki Sakatoku,Hiroshi Okamura,Satoru Nanno,Mitsutaka Nishimoto,Yasuhiro Nakashima,Hideo Koh,Masayuki Hino,Hirohisa Nakamae
Acquired hemophilia A (AHA) is a rare, life-threatening hemorrhagic disease caused by autoantibodies against factor VIII (FVIII), and bypassing agents (BPA) are used to control bleeding. However, some cases need a change of BPA or BPAs given sequentially or in combination for refractory bleeding. A 71-year-old man was admitted with subcutaneous hemorrhage. Laboratory investigations showed prolongation
-
Effects of frozen storage conditions and freezing rate on the stability of coagulation proteins in human plasma. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-19 Tereza Fenclova,Frantisek Marecek,Ingrid Hrachovinova
OBJECTIVES Degradation of coagulation proteins in frozen plasma may influence assay results. The aims of this study were to explore the changes in coagulation parameters in patient plasma and internal quality control (IQC) after different freezing and storage conditions during the short-term and long-term periods. METHODS Platelet poor plasma was prepared from citrated peripheral blood collected from
-
Left ventricular assist device thrombosis in the setting of supratherapeutic international normalized ratio (INR) and bleeding. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-19 Gaurav Gupta,Crystal L Yan,Tricia Kalwar,Nina Thakkar-Rivera
A 71-year-old female with heart failure who underwent left ventricular assist device (LVAD) placement presented for evaluation of low hemoglobin and dark stools. She also had leg pain, numbness, and weakness for which she was taking ibuprofen. She was found to have a gastrointestinal bleed, INR of 4.3, and arterial thrombi in the left leg. She was stabilized, had her anticoagulation held, and underwent
-
Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-18 Maya R Chilbert,Ashley E Woodruff,Marissa Saber,Pavel Goriacko,Mark Sinnet,David Jacobs
OBJECTIVE To compare the risk of readmissions for major bleeding within one year between apixaban and rivaroxaban as a component of triple antithrombotic therapy. METHODS This study was a multicenter, retrospective cohort study conducted at two academic medical centers in the Western New York and New York City region between July 1, 2011 and September 25, 2019. Adult patients were included if they
-
Association of single nucleotide polymorphisms (4G/5G) of plasminogen activator inhibitor-1 and the risk factors for placenta-related obstetric complications. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-17 Hanife Guler Donmez,Mehmet Sinan Beksac
BACKGROUND Placenta-related obstetric complications (PROCs) such as miscarriage, fetal growth restriction, preeclampsia, and preterm birth are the major causes of maternal and fetal morbidity and mortality. The objective of this study was to search the relevance of plasminogen activator inhibitor-1 (PAI-1) polymorphisms and co-morbidities and the risk factors for PROCs such as miscarriage, fetal growth
-
Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-17 Arjan van der Flier,Vu Hong,Zhan Liu,Peter Piepenhagen,Gregory Ulinski,Jennifer A Dumont,Kelly D Orcutt,Apollina Goel,Robert Peters,Joe Salas
Extended half-life recombinant FIX (rFIX) molecules have been generated to reduce the dosing burden and increase the protection of patients with hemophilia B. Clinical pharmacology studies with recombinant factor IX Fc fusion protein (rFIXFc) report a similar initial peak plasma recovery to that of rFIX, but with a larger volume of distribution. Although the pegylation of N9-GP results in a larger
-
HbA1c/C-peptide ratio is associated with angiographic thrombus burden and short-term mortality in patients presenting with ST-elevation myocardial infarction. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-17 Kenan Toprak,Mustafa Kaplangöray,Tolga Memioğlu,Mehmet İnanir,Bahadir Omar,Mustafa Beğenç Taşcanov,Asuman Biçer,Recep Demirbağ
OBJECTIVES Angiographic high thrombus burden (HTB) is associated with increased adverse cardiovascular events in patients with ST-elevation myocardial infarction (STEMI). HbA1c and C-peptide are two interrelated bioactive markers that affect many cardiovascular pathways. HbA1c exhibits prothrombogenic properties, while C-peptide, in contrast, exhibits antithrombogenic effects. In this study, we aimed
-
Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-07-06 Ambarina S Faiz,Shuang Guo,Ashwin Sridharan,Yong Lin,Claire S Philipp
Risk factors for venous thromboembolism (VTE) in elderly patients with acute myeloid leukemia (AML) are not known by race. The aim of this study was to determine the association of VTE with known risk factors and the impact of VTE on mortality in elderly white, black and Asian patients with AML. The merged SEER-Medicare database (2000-2015) was used for patients aged at least 65 years diagnosed with
-
A multicenter, observational study to evaluate hemostasis following recombinant activated FVII treatment in patients in Japan with congenital factor VII deficiency. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-23 Ikuo Seita,Ei Kinai
Reports describing symptoms and treatment of patients with congenital factor VII (FVII) deficiency frequently relate to patients in Europe, while only a small number describe data from Asian countries.This multicenter, prospective observational study (NCT01312636) collected data from 30 sites for 55% of patients registered in 2011 in Japan with congenital FVII deficiency treated with activated recombinant
-
Resolution of cardiac surgical bleeding with the combination of 4-factor prothrombin complex concentrate and fresh frozen plasma following lack of response to fresh frozen plasma alone in a patient with severe factor XI deficiency. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-21 Percy Boateng,Mala Varma,Lilyanne Chen,Hein Kyaw,Nay Lin Kyaw,Joseph Yoe
Factor XI deficiency is associated with a bleeding tendency in some patients. Factor XI helps to reduce fibrinolysis. Bleeding risk is increased in factor XI-deficient patients during surgeries with high fibrinolytic activity, including nasopharyngeal/oropharyngeal and genitourinary surgeries. Treatment options for factor XI-deficient patients include fresh frozen plasma (FFP), antifibrinolytics, recombinant
-
Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-19 Maximo J Marin,Carol M Mathew,Anita Rajasekhar,Marc Zumberg,Tammy Y Euliano,William E Winter,J Peter R Pelletier,Heather D Pruitt,Neil S Harris
Inherited dysfibrinogenemias are molecular disorders of fibrinogen that affect fibrin polymerization. The majority of cases are asymptomatic, but a significant proportion suffer from increased bleeding or thrombosis. We present two unrelated cases of dysfibrinogenemia, both of whom showed a characteristic discrepancy between fibrinogen activity and the immunologic fibrinogen. In one patient, the dysfibrinogenemia
-
Incidence of factor XII deficiency in critically ill patients with a prolonged activated partial thromboplastin time: a prospective observational study. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-19 Lipi Mishra,David Lee,Kwok M Ho
Limited data is available on factor XII deficiency in critically ill patients with prolonged activated partial thromboplastin time (aPTT). The association of factor XII deficiency with an increased risk of thromboembolism is unclear. This prospective observational study assessed the incidence of factor XII deficiency among critically ill patients with prolonged aPTT (>40 s), whether factor XII deficiency
-
Measuring coagulopathy in pediatric craniofacial surgery. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-12 Alexandra J Borst,Christopher M Bonfield,Poornachanda S Deenadayalan,Chi H Le,Meng Xu,Srijaya K Reddy
The goal of this study was to describe hematologic and coagulation laboratory parameters and identify if these laboratory studies could predict blood loss in a cohort of pediatric patients undergoing complex cranial vault reconstruction (CCVR) for repair of craniosynostosis. We reviewed records from 95 pediatric CCVR patients between 2015 and 2019. Primary outcome measures were hematologic and coagulation
-
Warfarin versus direct oral anticoagulants in South Asian octogenarians: a retrospective review. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-09 Samuel Cheng En Ee,Barbara Helen Rosario,Zi Huan Mok,Mon Hnin Tun,Siti Shafia Bte Yang Razali,Boon Hian Tan
To investigate the efficacy and safety outcomes of warfarin and direct oral anticoagulants in Asian octogenarians. A retrospective study was undertaken in 270 patients aged 80 years old and above, between 15 July 2015 and 21 December 2017, prescribed oral anticoagulation (OAC) with warfarin or direct oral anticoagulant (DOAC). Data collection included demographics, bleeding events, cessation of anticoagulation
-
Fibrinolytic drugs induced hemorrhage: mechanisms and solutions. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-06 Mingqing Tang,Chengjia Hu,Hongjun Lin,Hui Yan
Thrombosis has been emerging as a major global life-threatening issue with high mortality and serious complications, especially in the post-COVID-19 era. Compared with the commonly used plasminogen activators thrombolytic drugs, fibrinolytic drugs are no longer heavily dependent on the patients' own plasminogen, which are poorly expressed in most patients. As a novel "direct acting" thrombolytic agent
-
Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-02 Weronika Lebowa,Joanna Zdziarska,Tomasz Sacha
We present a case of a 30-year-old man suffering from chronic refractory immune thrombocytopenia (ITP) from early childhood. The patient was treated with all the therapeutic methods available in Poland, without platelet response: corticosteroids, intravenous immunoglobulins, splenectomy, cyclophosphamide, vinblastine, azathioprine, mycophenolate mofetil, rituximab, ciclosporin A, romiplostim, and eltrombopag
-
Obesity and physical exercise in hemophilia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Natalia Rodríguez Nieva
The new coagulation factors have made possible to increase the life expectancy of patients with hemophilia to around 70 years of age. However, there are some comorbidities to take into account such as obesity, hypertension, cardiovascular or metabolic diseases. Improving dietary habits and promoting physical exercise are the two ways of preventing this. But, less than 50% of people with haemophilia
-
Disability and the social impact of hemophilia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Montserrat García-Ripoll,Hortensia De la Corte-Rodríguez
In addition to receiving the medical treatment they need, people with hemophilia or other coagulopathies must acquire the strategies required to deal with the physical, emotional and social challenges they will encounter at the different stages of their lives. To this end, it is necessary to offer support for any uncertainty that may arise for the patient or parents upon diagnosis of the disease, and
-
Individualizing primary prophylaxis in patients with hemophilia A and B, adherence and new products. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Rubén Berrueco
The purpose of prophylaxis in hemophilic patients is to prevent bleeding. The latest guidelines of the World Hemophilia Federation recommend that all patients with a severe hemorrhagic phenotype should receive prophylactic treatment, defined as the regular administration of therapeutic products (either factor concentrates or nonfactor replacement treatments). These products are aimed at preserving
-
Haemophilic arthropathy: basic protocols for clinical examination and imaging. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 F Querol,F Querol-Giner,M Aguilar,S Bonanad,E Marqués,J M Blasco,S Pérez-Alenda
In haemophilia, screening protocols in the prevention and treatment of common lesions still require unification of criteria. Patients with haemophilia seek medical consultation exclusively for two reasons: because they have requested an appointment for a routine check-up (1-2 times a year in case of severe haemophilia) or because they have developed acute bleeding that requires treatment. The purpose
-
Orthopedic surgical procedures in people with hemophilia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Carlos A Encinas-Ullan,Hortensia De la Corte-Rodriguez,Primitivo Gomez-Cardero,E Carlos Rodriguez-Merchan
People with hemophilia tend to develop joint lesions secondary to the recurrent hemarthroses typical of their condition. These usually include chronic synovitis and arthropathy chiefly affecting their ankles, knees, and elbows. In addition, muscular hematomas, albeit less frequently, may also result in complications such as acute compartment syndrome, pseudotumors, bone cysts and peripheral nerve compression
-
Nonpharmacological treatment for coping with pain. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Ana Torres-Ortuño
Pain is one of the most common reasons for consultation and one of the most difficult tasks to handle for doctors. If it is chronic, the frequency of disorders increases associates that we cannot exclude from the treatment, and further complicates your treatment. The Asociation International Association for the Study of Pain (IAPS)1 defines the pain as "a sensory and emotional experience unpleasant
-
Hematological treatment and prophylaxis in patients with and without inhibitors. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Ana Marco-Rico
This document focuses on the hematological treatment and prophylaxis that should be indicated in three groups of patients with hemophilia: Patients with inhibitors; Patients without inhibitors; and Patients receiving nonfactor replacement therapy. Inhibitors contribute to refractoriness to replacement treatment, leading to more severe bleeds. Immunotolerance and bypassing agents are essential to eradicate
-
A contemporary approach to the musculoskeletal problems associated with hemophilia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Angel Martín Fuentes,María Elena Salas Gaude
It is essential that joint bleeds be treated in a hematologically and orthopedically optimal manner so as to arrest the bleeding as soon as possible and prevent potentially irreversible joint damage from setting in. The main goal of rehabilitation in the context of hemophilia is above all prevention and treatment of the consequences of musculoskeletal bleeding. Rehabilitation of acute joint bleeding
-
Chronic pain in haemophilia: assessment and analgesic treatment. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Hortensia De la Corte-Rodriguez,E Carlos Rodriguez-Merchan
People with haemophilia tend to experience pain from an early age because of venipuncture and hemarthrosis. If pain is not properly managed, it can become chronic and bedevil patients throughout their lives. Therapies are currently available that have been shown to effectively treat the different types of pain and their causes. Patients with haemophilia tend to experience either nociceptive or mixed
-
The predictive role of platelet count for bleeding in patients with hepatitis B virus and hepatitis C virus infection. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-05-31 Cih-En Huang,Jung-Jung Chang,Chih-Cheng Chen,Ying-Hsuan Wang,Chang-Hsien Lu,Yi-Yang Chen,Ting-Yao Wang,Min-Chi Chen
The impact of platelet count on bleeding in hepatitis B virus (HBV) and hepatitis C virus (HCV)-infected patients is unclear. We aimed to evaluate the relationship between platelet count and bleeding in patients with viral hepatitis. We selected patients with HBV and HCV infection. All esophagogastroduodenoscopy, colonoscopy, and brain imaging reports were reviewed to document upper gastrointestinal
-
The procoagulant potential before and after surgery for endometriosis and its association with disease severity. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-05-23 Amihai Rottenstreich,Yosef Kalish,Adi Gilan,Galia Spectre,Geffen Kleinstern,Uri Dior
OBJECTIVES Previous studies have suggested that endometriosis is associated with increased hypercoagulable state. We aimed to determine the procoagulant potential among women with endometriosis before and after surgery. METHODS A prospective longitudinal study performed during 2020-2021 at a university hospital. Women undergoing laparoscopic surgery for endometriosis served as the study group. Blood
-
Addressing the haemophilia healthcare crisis amidst Taliban rule: a call to action. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-06-01 Sayed Hamid Mousavi,Nooria Mohammady,Huma Homam,Fatema Rezaie
-
Importance of circulating monocyte subpopulations and Fcγ receptors in immune thrombocytopenia. Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-05-11 Amany A Abou-Elalla,Maha F Yacoub,Walaa Abdelfattah,Asmaa M Abdelhameed,Basma Samir Khereba,Mariam Onsy F Hanna
Monocytes have been linked to the pathogenesis of immune thrombocytopenia (ITP) because of their role in autoantibody-mediated platelet phagocytosis. However, monocytes constitute unique populations with major differences in expression for surface Fcγ receptors (FcγRs). Thus, we evaluated monocytes in whole blood samples from patients with newly diagnosed and chronic ITP. Monocyte subpopulations were
-
Prevalence and risk factors for pulmonary embolism in children with sickle cell disease: an institutional retrospective cohort study Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-05-04 Natasha Bala, Joseph Stanek, Vilmarie Rodriguez, Anthony Villella
The study was conducted to examine prevalence of pulmonary embolism in children with sickle cell disease (SCD) and identify potential risk factors associated with pulmonary embolism in a single tertiary paediatric centre. Children with SCD between 0 and 21 years of age from January 2010 to January 2021 were included. Pulmonary embolism was initially identified using International Classification of
-
Analysis of heparin-induced thrombocytopenia diagnostic and management strategies in individuals with inconclusive antibody optical densities Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-28 Bradley J. Erich, Jace Knutson, Brian J. Barnes
Heparin-induced thrombocytopenia (HIT) is an uncommon but serious complication of exposure to heparin. Antibody optical densities (ODs) used to diagnose HIT exceeding 2 are highly suggestive of disease, whereas ODs less than 0.5 often ‘rule out’ HIT. Variation in the clinical care of patients with inconclusive ODs between 0.5 and 2 is likely. This single-centre, retrospective analysis evaluates the
-
Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-13 Amina Arafat, Paolo Gennari, Atanas Ignatov, Svetlana Tchaikovski
Exposure to higher levels of steroid hormones, like that in pregnancy or during combined hormonal contraception, increases the risk of venous thromboembolism. Development of resistance to activated protein C (APC) thought to be the underlying pathomechanism of this prothrombotic state. This coagulation phenomena is largely to be explained by the hormone-induced impairment of the protein S/ tissue factor
-
Catastrophic antiphospholipid syndrome immediately after coronary angiography: the unexpected complication Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-12 Mario Raccis, Filippo Dossi, Alice Bernardelli, Milena Aste, Giovanni Berisso, Guido Parodi
A 44-year-old woman with obstetric antiphospholipid syndrome (APS) presented to our institution with suspected non ST-elevation myocardial infarction (NSTEMI). Shortly after coronary angiography, she developed diplopia, hypotension and chest pain with inferior ST elevation in 12-lead ECG. According to multidisciplinary evaluation, she promptly underwent systemic thrombolysis, with clinical and haemodynamic
-
Why do patients with antiphospholipid syndrome bleed? A clinical paradox Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-05 María Cynthia Fuentes-Lacouture, Lizeth Bustamante Gómez, Nicolás Torres, Carlos Arteaga-Unigarro
Although worldwide-known criteria of antiphospholipid syndrome include thrombotic and obstetric events, a moderate number of patients manifest with bleeding episodes during course of the disease, which is typically attributed to the long-term anticoagulation. However, these haemorrhagic manifestations sometimes are part of pathophysiological changes that might occur secondary to the disease that
-
Coexpression of factor VIII and factor von Willebrand variants in a woman with heavy menstrual bleeding Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-04 Alessandro Casini, Michal Yaron, Alexander Couzens, Pierre Fontana, Marguerite Neerman-Arbez
Heavy menstrual bleeding is one of the most common causes of consultation in haematology. We present the clinical case of a 20-year-old woman referred by her gynaecologist due to heavy menstrual bleeding since menarche, complicated by iron deficiency anaemia. Haemostasis work-up was initially suggestive of a von Willebrand disease type 1. Genetic analyses by whole exome sequencing lead to a fortuitous
-
Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation Blood Coagul. Fibrinolysis (IF 1.1) Pub Date : 2023-04-01 Laura H. Bukkems, Tine M.H.J. Goedhart, C. Michel Zwaan, Marjon H. Cnossen, Ron A.A. Mathôt
Objective Limited sampling strategies (LSS) lower the burden of pharmacokinetic (PK)-guided dosing, but an extensive evaluation of LSS for BAX 855 (Adynovi) is currently lacking. This study aimed to develop a LSS for BAX 855 and combine this with a LSS of a standard half-life (SHL) factor VIII (FVIII) concentrate in a clinical setting. Methods Individual PK parameters of BAX 855 were estimated for